PingShan Zhong, Kohei Nakata, Koki Oyama, Nobuhiro Higashijima, Akiko Sagara, Satomi Date, HaiZhen Luo, Masataka Hayashi, Akihiro Kubo, ChenYi Wu, Shan He, Takeo Yamamoto, Kazuhiro Koikawa, Chika Iwamoto, Toshiya Abe, Naoki Ikenaga, Kenoki Ohuchida, Takashi Morisaki, Yoshinao Oda, Keiji Kuba, Masafumi Nakamura
BACKGROUND: Although immune checkpoint blockade (ICB) therapy has proven to be extremely effective at managing certain cancers, its efficacy in treating pancreatic ductal adenocarcinoma (PDAC) has been limited. Therefore, enhancing the effect of ICB could improve the prognosis of PDAC. In this study, we focused on the histamine receptor H1 (HRH1) and investigated its impact on ICB therapy for PDAC. METHODS: We assessed HRH1 expression in pancreatic cancer cell (PCC) specimens from PDAC patients through public data analysis and immunohistochemical (IHC) staining...
May 8, 2024: Journal of Experimental & Clinical Cancer Research: CR